8-K: LENSAR Reports Record ALLY System Placements and 19% Procedure Volume Growth in Q2 2024

LENSAR achieved record placements of its ALLY system and a 19% increase in worldwide procedure volume in the second quarter of 2024, alongside securing key regulatory approvals.

Summary

• LENSAR reported its second quarter 2024 financial results, highlighting significant growth in several key areas.
• The company placed a record 17 ALLY Adaptive Cataract Treatment Systems during the quarter, the highest number since the product's launch.
• Worldwide procedure volumes increased by 19% compared to the same quarter last year, with US procedure volumes up by 16%.
• Total revenue for the quarter was $12.6 million, a 5% increase compared to $12.0 million in the second quarter of 2023.
• The installed base of ALLY systems grew to approximately 80, and the total installed base of LENSAR laser systems reached approximately 330.
• The company received Medical Device Regulation (MDR) certification (CE Mark) and Taiwan FDA approval for commercial distribution of the ALLY system.
• The company's backlog of ALLY systems pending installation totaled 17 as of June 30, 2024.
• Net loss for the quarter was $9.0 million, or ($0.79) per share, compared to a net loss of $8.8 million, or ($0.81) per share, in the same quarter of 2023.
• Adjusted EBITDA for the quarter was $30,000, compared to ($0.2) million in the second quarter of 2023.
• The company had $15.4 million in cash, cash equivalents, and investments as of June 30, 2024, down from $24.6 million at the end of 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth in key metrics like system placements and procedure volumes. However, the net loss and decrease in cash reserves temper the overall sentiment.

Positives

• The company achieved a record number of ALLY system placements, indicating strong market adoption.
• Significant growth in worldwide procedure volumes demonstrates increased utilization of LENSAR's technology.
• The CE Mark and Taiwan FDA approvals open up new international markets for the ALLY system.
• The increase in revenue across all lines indicates a healthy business performance.
• The company achieved break-even on an Adjusted EBITDA basis for the quarter.
• The installed base of ALLY systems and total laser systems continues to grow.

Negatives

• The company reported a net loss of $9.0 million for the quarter.
• Cash, cash equivalents, and investments decreased from $24.6 million at the end of 2023 to $15.4 million as of June 30, 2024.
• The company recorded a $3.7 million impairment charge on intangible assets.
• EBITDA was ($8.3) million for the quarter, compared with ($8.0) million for the same quarter last year.

Risks

• The company has a history of operating losses and needs to achieve and sustain profitability.
• The company's ability to commercialize the ALLY system and maintain its LENSAR Laser System is subject to regulatory risks.
• Global macroeconomic conditions could impact the company's business, financial condition, and results of operations.
• The company faces competition from other companies with more established products and greater resources.
• The company's future capital needs and ability to raise additional funds are uncertain.
• The company is exposed to credit risk from its customers.
• The company's ability to secure adequate coverage or reimbursement by government or other third-party payors for procedures using the ALLY System is a risk.

Future Outlook

The company anticipates continued growth in recurring revenue as it expands its installed base of ALLY systems and expects to drive market share growth beyond the U.S. following recent regulatory approvals.

Management Comments

• Nick Curtis, President and CEO of LENSAR, stated that the second quarter was a period of solid growth driven by record ALLY system placements and increased worldwide procedure volume.
• He also noted that a majority of the quarter's placements and backlog came from new practices adopting LENSAR's technology.

Industry Context

The announcement reflects a positive trend in the adoption of advanced laser cataract surgery technology, with LENSAR's ALLY system gaining traction in the market. The CE Mark approval positions LENSAR to compete more effectively in the European market, where there is a growing demand for advanced cataract treatment options.

Comparison to Industry Standards

• While specific competitor data is not provided, the 19% increase in worldwide procedure volume suggests strong market adoption compared to industry averages.
• The 17 ALLY system placements in a single quarter is a significant achievement, indicating a competitive edge in the market.
• The company's focus on recurring revenue through system placements and procedure volume aligns with industry best practices for medical device companies.
• The achievement of break-even on an Adjusted EBITDA basis is a positive sign, indicating improved operational efficiency compared to previous quarters.

Stakeholder Impact

• Shareholders may view the increased system placements and procedure volumes positively, but the net loss and cash burn may raise concerns.
• Employees may be encouraged by the company's growth and expansion into new markets.
• Customers (surgeons and medical facilities) will benefit from the availability of the ALLY system and its advanced features.
• Suppliers may see increased demand for components used in the ALLY system.
• Creditors may be concerned about the company's cash burn and net loss.

Next Steps

• LENSAR will continue to focus on expanding its installed base of ALLY systems.
• The company will pursue further regulatory approvals for the ALLY system in additional markets.
• LENSAR will work to increase recurring revenue through procedure volume growth.
• The company will host a conference call to discuss the second quarter results and provide a business update.

Key Dates

Keywords

ALLY System, Cataract Treatment, Medical Device, Laser Technology, Procedure Volume, Regulatory Approval, EBITDA, Revenue, LENSAR, MDR, CE Mark